Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Gastrointestinal and Other Cancers
Sponsor
National Cancer Institute (NCI)
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02521285
This randomized phase II trial studies the safety of and how well aspirin works in preventing
Barrett's esophagus from returning after it has been successfully eliminated by
radiofrequency ablation. Studying samples of tissue from patients with Barrett's esophagus
for the levels of a specific protein that is linked to developing Barrett's esophagus may
help doctors learn whether aspirin can prevent it from returning after it has been
successfully treated.
Barrett's esophagus from returning after it has been successfully eliminated by
radiofrequency ablation. Studying samples of tissue from patients with Barrett's esophagus
for the levels of a specific protein that is linked to developing Barrett's esophagus may
help doctors learn whether aspirin can prevent it from returning after it has been
successfully treated.
Intervention
Aspirin, Laboratory Biomarker Analysis, Questionnaire Administration, Placebo Administration
Condition
Barrett Esophagus
Investigators
Robert S Bresalier